Moleculin Biotech(MBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MBRX Moleculin Biotech

Closed Good Friday 04-17 16:00:00 EDT

0.8749

-0.0441

-4.80%

盘后0.8744

-0.0005-0.06%

19:28 EDT

High0.9403	Low0.8450	Vol272.75K
Open0.9000	D1 Closing0.9190	Amplitude10.37%
Mkt Cap12.25M	Tradable Cap10.91M	Total Shares14.00M
T/O242.80K	T/O Rate2.19%	Tradable Shares12.47M
P/B2.05	ROE-135.80%	EPS-6.32
52wk High5.47	52wk Low0.3975	P/E-0.14
Dividend0.00	Div.Yield0.00	ROA-60.39%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"MBRX","market":"US","secType":"STK","nameCN":"Moleculin Biotech","latestPrice":0.8749,"timestamp":1744920000000,"preClose":0.919,"halted":0,"volume":272749,"hourTrading":{"tag":"盘后","latestPrice":0.8744,"preClose":0.8749,"latestTime":"19:28 EDT","volume":2177,"amount":1908.264,"timestamp":1744932510789},"delay":0,"floatShares":12468113,"shares":14000494,"eps":-6.320946,"marketStatus":"Closed Good Friday","change":-0.0441,"latestTime":"04-17 16:00:00 EDT","open":0.9,"high":0.9403,"low":0.845,"amount":242795.88210685,"amplitude":0.1037,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.320946,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.919,"preHourTrading":{"tag":"盘前","latestPrice":0.9011,"preClose":0.919,"latestTime":"09:29 EDT","volume":1484,"amount":1344.3587164,"timestamp":1744896572525},"postHourTrading":{"tag":"盘后","latestPrice":0.8744,"preClose":0.8749,"latestTime":"19:28 EDT","volume":2177,"amount":1908.264,"timestamp":1744932510789},"volumeRatio":0.761567066197277},"requestUrl":"/m/hq/s/MBRX","defaultTab":"news","newsList":[{"id":"2528120957","title":"Moleculin Biotech’s Annamycin Highlighted at AACR 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528120957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528120957?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:58","pubTimestamp":1744894716,"startTime":"0","endTime":"0","summary":"Moleculin Biotech ( ($MBRX) ) has shared an announcement. On April 17, 2025, Moleculin Biotech announced that their abstract on Annamycin, a next-g...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moleculin-biotechs-annamycin-highlighted-at-aacr-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moleculin-biotechs-annamycin-highlighted-at-aacr-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2528712690","title":"BRIEF-Moleculin Announces Acceptance Of Abstract To Be Presented At The American Association For Cancer Research Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528712690","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528712690?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:54","pubTimestamp":1744894440,"startTime":"0","endTime":"0","summary":"BRIEF-Moleculin Announces Acceptance Of Abstract To Be Presented At The American Association For Cancer Research Annual Meeting 2025April 17 (Reuters) - Moleculin Biotech Inc MBRX.O:MOLECULIN ANNOUNCE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA9QSWDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2528603711","title":"Moleculin Announces Acceptance of Abstract to Be Presented at the American Association for Cancer Research (Aacr) Annual Meeting 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2528603711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528603711?lang=en_us&edition=full_marsco","pubTime":"2025-04-17 20:30","pubTimestamp":1744893001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA9QSWDL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2524498070","title":"Moleculin Biotech doses first patient in Phase 3 MIRACLE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524498070","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524498070?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 20:41","pubTimestamp":1743597695,"startTime":"0","endTime":"0","summary":"Moleculin Biotech  announced the first patient has been dosed in its Phase 3 pivotal trial evaluating Annamycin in combination with Cytarabine for the treatment of AML patients who are refractory to or relapsed after induction therapy. This Phase 3 “MIRACLE” trial is a global approval trial, including sites in the US, Europe and the Middle East. “The start of patient dosing represents a huge milestone for Moleculin and importantly, the AML community,” commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “Our team remains focused on bringing clinical sites online in the U.S., Europe and Middle East and enrolling patients to build on this momentum. With the progress made to date, we expect to unblind preliminary data from the first 45 subjects in the second half of this year, a near-term, potentially value-driving milestone that will provide key insight as we continue to advance Annamycin’s development towards approval.”Discover the latest stocks recommended by top ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/moleculin-biotech-doses-first-patient-124135108.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moleculin-biotech-doses-first-patient-124135108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Moleculin Biotech doses first patient in Phase 3 MIRACLE trial","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2524014113","title":"BRIEF-Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524014113","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524014113?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:32","pubTimestamp":1743510737,"startTime":"0","endTime":"0","summary":"BRIEF-Moleculin Doses First Patient In Pivotal, Adaptive Phase 3 Miracle TrialApril 1 (Reuters) - Moleculin Biotech Inc MBRX.O:MOLECULIN DOSES FIRST PATIENT IN PIVOTAL, ADAPTIVE PHASE 3 MIRACLE TRIALM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUAB2NJNQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2524911589","title":"Moleculin Biotech Inc - Preliminary Data From First 45 Subjects Expected in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524911589","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524911589?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:30","pubTimestamp":1743510601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUAB2NJNQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2524113231","title":"Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 Miracle Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524113231","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524113231?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:30","pubTimestamp":1743510601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUAB2NJNQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2524829119","title":"Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524829119","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524829119?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 20:30","pubTimestamp":1743510600,"startTime":"0","endTime":"0","summary":"– Initial data readout on track for second half of 2025. “The start of patient dosing represents a huge milestone for Moleculin and importantly, the AML community,” commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. “Our team remains focused on bringing clinical sites online in the U.S., Europe and Middle East and enrolling patients to build on this momentum. With the progress made to date, we expect to unblind preliminary data from the first 45 subjects in the second half of this year, a near-term, potentially value-driving milestone that will provide key insight as we continue to advance Annamycin’s development towards approval.”For Part B of the trial, approximately 220 additional subjects will be randomized to receive either HiDAC plus placebo or HiDAC plus the optimum dose of Annamycin . T","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moleculin-doses-first-patient-pivotal-123000906.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2522339229","title":"All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522339229","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522339229?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 00:00","pubTimestamp":1743004808,"startTime":"0","endTime":"0","summary":"Investors might want to bet on Moleculin Biotech, Inc. , as it has been recently upgraded to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.Therefore, the Zacks rating upgrade for Moleculin Biotech basically reflects positivity about its earnings outlook that could translate into b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/know-moleculin-biotech-mbrx-rating-160008438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MBRX"],"gpt_icon":0},{"id":"2522710300","title":"Moleculin Biotech Raised to Buy From Hold by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2522710300","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522710300?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 21:22","pubTimestamp":1742908920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2025 09:22 ET (13:22 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX"],"gpt_icon":0},{"id":"2522202245","title":"Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2522202245","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522202245?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 20:03","pubTimestamp":1742904202,"startTime":"0","endTime":"0","summary":"Maxim Upgrades Moleculin Biotech to Buy From Hold, Price Target is $4","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MBRX"],"gpt_icon":0},{"id":"2522021896","title":"Moleculin Biotech Inc : Maxim Group Raises to Buy From Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2522021896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522021896?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:42","pubTimestamp":1742902970,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q814D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2522060941","title":"Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2522060941","media":"GuruFocus.com","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522060941?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 15:00","pubTimestamp":1742886031,"startTime":"0","endTime":"0","summary":"Cash Balance: Approximately $13 million as of the end of the year, including $9 million raised in February 2025.Operating Expenses: Reduced by about $3 million in 2024 compared to 2023.Market Cap: $16.2 million with 14 million shares outstanding.Phase 2 Clinical Trial Results: 50% complete remission rate in second-line AML patients treated with Annamycin plus high-dose Cytarabine.Overall Survival: 11 months for second-line therapy patients in the Phase 2 trial.Progression-Free Survival: Median of 9 months in the Phase 2 trial.Phase 3 MIRACLE Trial: Designed to compare Annamycin plus high-dose Cytarabine against placebo plus high-dose Cytarabine.Interim Data Unblinding: Planned after 45 and between 75-90 subjects in the Phase 3 trial.Shares Trading Volume: Trailing one-year trading volume of 1.4 million shares per day.GuruFocus has detected 1 Warning Sign with MBRX.Moleculin Biotech Inc  has initiated the MIRACLE Phase 3 pivotal trial for Annamycin, targeting relapsed and refractory AML","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/moleculin-biotech-inc-mbrx-q4-070031672.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MBRX"],"gpt_icon":0},{"id":"2522613070","title":"Q4 2024 Moleculin Biotech Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2522613070","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522613070?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 13:38","pubTimestamp":1742881097,"startTime":"0","endTime":"0","summary":"Walter Klemp; Chairman of the Board, President, Chief Executive Officer; Moleculin Biotech Inc. Jonathan Foster; Chief Financial Officer, Executive Vice President; Moleculin Biotech Inc. Thank you, operator. Good morning, everyone, and thanks for joining us today. I'd like to kick things off with a brief overview of where we are. The entire Moleculin team has been laser focused on the launch of the MIRACLE Phase 3 pivotal trial for Annamycin. Now, this is a study designed to win approval for Annamycin in combination with Cytarabine for the second line treatment of relapsed and refractory AML patients. This is a glob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-moleculin-biotech-inc-053817308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MBRX"],"gpt_icon":0},{"id":"2522603052","title":"Moleculin Biotech Advances Clinical Trials Amid Financial Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2522603052","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522603052?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 11:54","pubTimestamp":1742874853,"startTime":"0","endTime":"0","summary":"Moleculin Biotech ( ($MBRX) ) has released its Q4 earnings. Here is a breakdown of the information Moleculin Biotech presented to its investors. Mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moleculin-biotech-advances-clinical-trials-amid-financial-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moleculin-biotech-advances-clinical-trials-amid-financial-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2522709218","title":"Moleculin Biotech Price Target Maintained With a $8.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522709218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522709218?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 02:59","pubTimestamp":1742842740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 14:59 ET (18:59 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX"],"gpt_icon":0},{"id":"2521473137","title":"Moleculin Biotech Shares Corporate Presentation Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521473137","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521473137?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:48","pubTimestamp":1742816884,"startTime":"0","endTime":"0","summary":"Moleculin Biotech ( ($MBRX) ) just unveiled an update. On March 24, 2025, Moleculin Biotech, Inc. utilized a corporate presentation for its website...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moleculin-biotech-shares-corporate-presentation-update-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moleculin-biotech-shares-corporate-presentation-update-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBRX","BK4139"],"gpt_icon":0},{"id":"2521741840","title":"Moleculin Biotech FY 2024 GAAP EPS $(6.32) Misses $(3.84) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521741840","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521741840?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:22","pubTimestamp":1742815364,"startTime":"0","endTime":"0","summary":"Moleculin Biotech FY 2024 GAAP EPS $(6.32) Misses $(3.84) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44455001/moleculin-biotech-fy-2024-gaap-eps-6-32-misses-3-84-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBRX"],"gpt_icon":0},{"id":"2521874668","title":"Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2521874668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521874668?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:05","pubTimestamp":1742814300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA8RKGZ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MBRX"],"gpt_icon":0},{"id":"2521746912","title":"Moleculin Biotech Inc:  Initial Data Readout of Phase 3 Miracle Trial Expected in the Second Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521746912","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521746912?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 19:05","pubTimestamp":1742814300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUA8RKGZ7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBRX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moleculin.com","stockEarnings":[{"period":"1week","weight":0.1967},{"period":"1month","weight":-0.1973},{"period":"3month","weight":-0.5346},{"period":"6month","weight":-0.6615},{"period":"1year","weight":-0.7956},{"period":"ytd","weight":-0.4854}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.050477},{"month":2,"riseRate":0.222222,"avgChangeRate":-0.078146},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.125735},{"month":4,"riseRate":0.333333,"avgChangeRate":0.058182},{"month":5,"riseRate":0.125,"avgChangeRate":-0.061505},{"month":6,"riseRate":0.25,"avgChangeRate":0.124538},{"month":7,"riseRate":0.555556,"avgChangeRate":0.074026},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.100133},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.080426},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.142911},{"month":11,"riseRate":0.555556,"avgChangeRate":0.056416},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.064984}],"exchange":"NASDAQ","name":"Moleculin Biotech","nameEN":"Moleculin Biotech"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Moleculin Biotech(MBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Moleculin Biotech(MBRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Moleculin Biotech,MBRX,Moleculin Biotech股票,Moleculin Biotech股票老虎,Moleculin Biotech股票老虎国际,Moleculin Biotech行情,Moleculin Biotech股票行情,Moleculin Biotech股价,Moleculin Biotech股市,Moleculin Biotech股票价格,Moleculin Biotech股票交易,Moleculin Biotech股票购买,Moleculin Biotech股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Moleculin Biotech(MBRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Moleculin Biotech(MBRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}